TW200640466A - Method of treatment - Google Patents

Method of treatment

Info

Publication number: TW200640466A
Authority: TW; Taiwan
Prior art keywords: related disorders; disorders; substance; pharmaceutically acceptable; limited
Prior art date: 2005-01-07

Application number

TW095100687A

Other languages

English (en)

Chinese (zh)

Inventor

Patricia C Davis

Jeffrey M Goldstein

Scott W Grimm

Helen R Winter

Raymond F Suckow

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-07

Filing date

2006-01-06

Publication date

2006-12-01

2006-01-06 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2006-12-01 Publication of TW200640466A publication Critical patent/TW200640466A/zh

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
208000011117 substance-related disease Diseases 0.000 abstract 3
208000035475 disorder Diseases 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 abstract 1
208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
208000030990 Impulse-control disease Diseases 0.000 abstract 1
208000003863 Marijuana Abuse Diseases 0.000 abstract 1
208000026251 Opioid-Related disease Diseases 0.000 abstract 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
231100000643 Substance intoxication Toxicity 0.000 abstract 1
208000028505 alcohol-related disease Diseases 0.000 abstract 1
229940025084 amphetamine Drugs 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
235000014632 disordered eating Nutrition 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
208000030459 obsessive-compulsive personality disease Diseases 0.000 abstract 1
208000022821 personality disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 abstract 1
229950010883 phencyclidine Drugs 0.000 abstract 1
239000000932 sedative agent Substances 0.000 abstract 1
230000001624 sedative effect Effects 0.000 abstract 1
201000009032 substance abuse Diseases 0.000 abstract 1
231100000736 substance abuse Toxicity 0.000 abstract 1
201000006152 substance dependence Diseases 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

TW095100687A 2005-01-07 2006-01-06 Method of treatment TW200640466A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US64226205P	2005-01-07	2005-01-07
US73786405P	2005-11-18	2005-11-18
US73786505P	2005-11-18	2005-11-18
US73788705P	2005-11-18	2005-11-18

Publications (1)

Publication Number	Publication Date
TW200640466A true TW200640466A (en)	2006-12-01

Family

ID=36647771

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095100687A TW200640466A (en)	2005-01-07	2006-01-06	Method of treatment

Country Status (6)

Country	Link
EP (1)	EP1838325A1 (fr)
JP (1)	JP2008526839A (fr)
AR (1)	AR052191A1 (fr)
TW (1)	TW200640466A (fr)
UY (1)	UY29326A1 (fr)
WO (1)	WO2006073360A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009516708A (ja) *	2005-11-18	2009-04-23	アストラゼネカ・アクチエボラーグ	液体製剤
CA2728675A1 (fr)	2008-06-20	2009-12-23	Astrazeneca Ab	Derives de dibenzothiazepine et leur utilisation
WO2010085976A1 (fr) *	2009-01-30	2010-08-05	F.I.S. Fabbrica Italiana Sintetici S.P.A.	Procédé pour la synthèse de quétiapine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3539573A (en) *	1967-03-22	1970-11-10	Jean Schmutz	11-basic substituted dibenzodiazepines and dibenzothiazepines
GB8607684D0 (en) *	1986-03-27	1986-04-30	Ici America Inc	Thiazepine compounds
US7071133B2 (en) *	1993-11-16	2006-07-04	Ppg Industries Ohio, Inc.	Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift
US5602124A (en) *	1994-12-12	1997-02-11	Allelix Biopharmaceuticals, Inc.	5-HT2 receptor ligands
SE0003126D0 (sv) *	2000-09-05	2000-09-05	Astrazeneca Ab	Method of treatment
DE60219761T2 (de) *	2001-02-06	2008-01-17	Astrazeneca Ab	Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
CA2502787A1 (fr) *	2002-10-18	2004-04-29	Massachusetts Mental Health Institute	Traitement de l'abus d'alcool et/ou de substances par antagonisme vis-a-vis des recepteurs alpha2-adrenergiques avec fabile blocage de la dopamine
BRPI0412127A (pt) *	2003-07-02	2006-08-15	Astrazeneca Ab	método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma
CA2547652A1 (fr) *	2003-12-04	2005-06-16	The Research Foundation Of The City University Of New York	Effets de la clozapine et de la cocaine sur la liberation de dopamine et de serotonine dans le noyau accumbens pendant un comportement psychostimulant et sevrage
BRPI0417749A (pt) *	2003-12-22	2007-04-10	Acadia Pharm Inc	composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
US20050171088A1 (en) *	2004-01-30	2005-08-04	Astrazeneca Ab	Treatment of psychoses with dibenzothiazepine antipsychotic

2006
- 2006-01-04 EP EP06700349A patent/EP1838325A1/fr not_active Withdrawn
- 2006-01-04 JP JP2007550327A patent/JP2008526839A/ja active Pending
- 2006-01-04 WO PCT/SE2006/000009 patent/WO2006073360A1/fr not_active Ceased
- 2006-01-05 UY UY29326A patent/UY29326A1/es not_active Application Discontinuation
- 2006-01-06 AR ARP060100058A patent/AR052191A1/es not_active Application Discontinuation
- 2006-01-06 TW TW095100687A patent/TW200640466A/zh unknown

Also Published As

Publication number	Publication date
WO2006073360A1 (fr)	2006-07-13
JP2008526839A (ja)	2008-07-24
EP1838325A1 (fr)	2007-10-03
AR052191A1 (es)	2007-03-07
UY29326A1 (es)	2006-08-31

Similar Documents

Publication	Publication Date	Title
WO2004032836A3 (fr)	2004-06-10	Inhibiteurs de la dipeptidyl peptidase heterocyclique beta-amino utiles pour le traitement ou la prevention du diabete
MA28469B1 (fr)	2007-03-01	Inhibiteurs de la dipeptidyle peptidase
ATE548354T1 (de)	2012-03-15	Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
WO2007041365A3 (fr)	2007-06-21	Composes organiques
WO2004037169A3 (fr)	2004-08-05	Inhibiteurs de dipeptidylpeptidase heterocyclique beta-amino destines au traitement ou a la prevention de diabetes
WO2003082817A3 (fr)	2003-12-18	Inhibiteurs de la dipeptidyl peptidase beta-amino heterocycliques pour le traitement ou la prevention du diabete
MX2008001549A (es)	2008-04-04	3,11b-cis-dihidrotetrabenazina para el tratamiento de esquizofrenia y otras psicosis.
DE60330485D1 (de)	2010-01-21	Zur behandlung von diabetes
PL2026803T3 (pl)	2012-05-31	Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
WO2004018419A3 (fr)	2004-06-03	Quinolinones de benzimidazole et leurs utilisations
TNSN06315A1 (en)	2007-12-03	Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
MY127961A (en)	2007-01-31	Beta-amino heterocyclic dipetidyl peptidase inhibitors for the treament or prevention of diabetes
DE502005008916D1 (de)	2010-03-11	Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
AU2016216625A1 (en)	2016-09-15	Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
WO2006017673A3 (fr)	2007-04-12	Influence du taj sur les fonctions neuronales
WO2007006003A3 (fr)	2009-04-30	Combinaisons d'eszopiclone et de trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphtalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphtalenamine, et methodes de traitement de la menopause et des troubles de l'humeur, de l'anxiete et troubles cognitifs
WO2006088951A3 (fr)	2007-03-15	Chimiotaxie à modulation de cd38
MY142252A (en)	2010-11-15	Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
TNSN00106A1 (fr)	2005-11-10	Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
WO2005075450A3 (fr)	2006-03-30	Nouveaux composes spiro-pentacycliques
ATE401327T1 (de)	2008-08-15	Pyrroloimidazolderivate ,verfahern zu ihrer herstellung, diese enthaltende zusammensetzungen, und ihre verwendung als nootropika
TW200616644A (en)	2006-06-01	Medicine for prevention or treatment of diabetes
WO2007051785A3 (fr)	2007-09-07	Utilisation de sdf-1 pour le traitement et/ou la prevention de maladies neurologiques
BR0315225A (pt)	2005-08-23	Uso de diidroimidazolonas para o tratamento de epilepsia em cachorros
ATE326223T1 (de)	2006-06-15	Methode zur behandlung der hyperaktiven blase